Contineum Therapeutics
Daniel S. Lorrain is the Chief Scientific Officer at Contineum Therapeutics. Prior to their current role, Daniel S. held positions such as Vice President of Biology at Inception Sciences, Inc., Executive Director and Head of Biology at Amira Pharmaceuticals, and Research Fellow at Merck. With a background in Behavioral Neuroscience, Daniel has been involved in small molecule drug discovery in various therapeutic areas including neurodegeneration, fibrosis, oncology, and hearing loss. Daniel S. was also part of the team that led to the acquisition of Inception Neuroscience Program by Roche, launching the successor company, Pipeline Therapeutics.
Contineum Therapeutics
Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with high unmet need. Contineum targets biological pathways associated with specific clinical disabilities, that once modulated, can demonstrably impact the course of disease.